Looking at the argument you've presented objectively, I can't say that I disagree with much of what you've written. Perhaps you picked up the eventual flattening of Nextstellis earlier than I did. Back in 2022-23 they reported script sales on a monthly basis and these were quite volatile, the November, December January growth were +5%,-5% and 10.5% before that there were also negative figures and high teens but here we are again where the two quarterly figures reported hence are +5.9% QoQ or +1.8% MoM for 3QFY or +10.4%QoQ or +3.4% MoM for 4QFY, we will know next week what the trajectory is for the last 4 months.
Just as a sober comparison, Gedeon Richter reported their 3Q performance a few days ago and reported Drovelis sales grew 52% YoY which is about 3.3% MoM so they're also not growing market share any quicker than what we are and just maybe that is the growth rate we should expect and not the 9% seen in 2022-23. Even so, with 3.4% MoM growth we will have a profitable product it will just take longer.
I also don't disagree with your assessment of the TherepeuticsMD products, we were slow off the mark marketing these products in the first few months and the last few months, I have interpreted as growth and you as back to normal both interpretations are possible once again we will know more next week.
I will add one more comment which tilts my belief more to the growth side and that is that the CEO was aware of the slow down by Xmas last year when he began to restructure the WH sales team, this new team and leadership has now been in place for a few months and just maybe the turnaround in the last quarter is a sign of improvement and not just volatility of the figures.
MYX Price at posting:
$4.88 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)